Pretreatment with gonadotropin-releasing hormone antagonist protects against chemotherapy-induced testicular damage in mice
Background: Testicular toxicity following chemotherapy is of increasing importance with the continuous improvement of survival rates. Gonadotropin-releasing hormone (GnRH) was suggested to protect testis against such toxicity; however, its suppressive quality and mechanism of action are still unclea...
Main Authors: | Mattan Levi, Ruth Shalgi, Irit Ben-Aharon |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2022-10-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/17588359221113274 |
Similar Items
-
Anti-HER2/neu Antibody Reduces Chemotherapy-Induced Ovarian Toxicity—From Bench to Bedside
by: Mattan Levi, et al.
Published: (2020-12-01) -
Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix
by: Kristof Chwalisz, M.D., Ph.D.
Published: (2023-06-01) -
The use of gonadotropin-releasing hormone antagonist in women undergoing intrauterine insemination
by: M Yousef Elsemary, et al.
Published: (2019-01-01) -
Gonadotropin-Releasing Hormone Antagonists—A New Hope in Endometriosis Treatment?
by: Anna Maria Rzewuska, et al.
Published: (2023-01-01) -
Cancer During Pregnancy: The Role of Vascular Toxicity in Chemotherapy-Induced Placental Toxicity
by: Hadas Bar-Joseph, et al.
Published: (2020-05-01)